Medrogestone

Summary

Medrogestone (CHEMBL2106825) is an approved small molecule (ATC G03DB03).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G03DB03
• Chemistry: 340.5 Da · C23H32O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2106825
Name	Medrogestone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9949848
ATC	G03DB03
Molecular formula	C23H32O2
Molecular weight	340.5
InChIKey	HCFSGRMEEXUOSS-JXEXPEPMSA-N

SMILES: CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@]3(C)C(=O)C)C)[C@@]4(C1=CC(=O)CC4)C

IUPAC name: (8R,9S,10R,13S,14S,17S)-17-acetyl-6,10,13,17-tetramethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one

Also known as: AY 62022, AY-13615, AY-13615S, AY-62022, Colpro, Colprone, Etogyn, Medrogesterone, Medrogestona, Medrogestone, Metrogestone, NSC-123018

Patent coverage: 797 distinct patent families (3,009 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).